Teewinot Life Sciences Corporation Announces Breakthrough Commercial Production of the Cannabinoid Varin Series


Teewinot Life Sciences Corporation (Teewinot), a global leader in the use of biosynthetic processes for the production of kilogram quantities of pharmaceutical grade cannabinoids, announced today that its wholly owned subsidiary, Full Spectrum Laboratories, Ltd. (FSL), can produce commercial quantities of THCVA, CBDVA, CBCVA, and CBGVA (varin series) using its proprietary CannSynthesisTM technology. Teewinot and FSL are recognized as pioneers in synthesizing pharmaceutically important cannabinoids. It is not practical to commercially produce the varin series compounds by means of plant extraction because the Cannabis plant only produces small quantities of these cannabinoids. FSL has developed patent-protected biosynthetic processes for the manufacture of THCVA, CBDVA, CBCDA, and CBGVA using enzymes such as THCA synthase and CBDA synthase.

Dr. Richard Peet, Executive Vice President of Teewinot and co-inventor of the CannSynthesisTM technology stated, “Our proprietary CannSynthesisTM process makes possible the cost-effective production of commercial quantities of pharmaceutically pure cannabinoids that are produced in relatively small quantities by the Cannabis plant. Using FSL’s revolutionary biosynthetic process, it is now possible to envision treating patients with cannabinoids that are impractical to cost-effectively produce in commercial quantities by plant extraction or chemical synthesis.”

Jeffrey M. Korentur, Teewinot President and CEO says, “It’s hard to overstate the significance that this expansion of our manufacturing catalog provides. Researchers around the world are demanding better access to this important, and demonstrably effective sub-set of cannabinoids, and Teewinot is excited to be the market leader in this space. Until now, there has been no commercially reliable method of producing these molecules. The CannSynthesisTM process ensures global availability of the varin series at a reasonable cost, and with a supply chain that can effortlessly scale to meet the demands of the market. CannSynthesisTM eliminates the risks associated with agricultural and chemical production methods, yet provides the purest cannabinoids to the research, medical and pharmaceutical communities.”

Teewinot is the global leader for commercial production of pharmaceutically pure (>99%) THCA, CBDA, CBCA, CBGA, THCVA, CBDVA, CBCVA, and CBGVA. Teewinot seeks partners interested in working to commercialize these important cannabinoids and provide patients with new healthcare solutions.

For more information, please visit www.tlscorp.com or follow us on Twitter (@teewinot_corp).



February 21, 2017


Topic Area: Press Release


Recent Posts

Harris Health to Build New Freestanding Cancer Center

The center is planned to open in 2029, following the opening of the new O'Quinn Hospital along the North Loop at Lockwood.


Inland Empire Health Plan Opens Expanded San Bernardino Community Wellness Center

The new 33,000-square-foot center is nearly three times the size of the original location off Second Street.


Rethinking Parking Lot Design at Irvine Heritage Medical Plaza

A new solar installation shows how healthcare facilities can improve parking amenities while boosting energy savings


Repurposing Healthcare Spaces: 5 Critical Questions

Done well, converting existing spaces can trim upfront project costs by up to 40 percent, compared with ground-up construction


Disinfectant Contact Time: The Case for Biofilm Disruption

Contact time, while essential for compliance, does not reliably predict microbial reduction on actual healthcare surfaces.


 
 


FREE Newsletter Signup Form

News & Updates | Webcast Alerts
Building Technologies | & More!

 
 
 


All fields are required. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.